Editas Medicine, Inc. Common Stock (EDIT) — 分析摘要
Editas Medicine, Inc. Common Stock（EDIT）的市值为441.97百万美元，最近一年的营收同比增长了+25.4%。净利润率为-395.0%。当前市盈率为-4.1倍。
核心要点
- 营收同比变化+25.4%
- 净利润率-395.0%
- 市盈率-4.1倍
与BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)板块的其他公司相比，EDIT的营收增长为+25.4%，市盈率为-4.1倍。
Editas Medicine, Inc. Common Stock (EDIT)
更新 — ET · 来源 POLYGON
红旗与风险提示高风险信号
存在多项实质性红旗，在依赖任何估值输出前应先重点核查这些风险。
利息保障倍数为 -22.2x — 盈利不足以覆盖利息支出
D/E 为 12.4x — 杠杆极高
营业利润率为 -281.3% — 严重经营亏损
净利率为 -281.6% — 亏损超过收入（可能含一次性费用）
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary gene editing platform based on CRISPR technology and continues to expand its capabilities. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1). The company has a single operating segment, which is the business of developing and commercializing gene editing technology.
行业
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
员工人数
87
总部
CAMBRIDGE, MA
Exchange
XNAS
基于 4 年财务数据的系统性竞争优势评估
此评估基于历史财务数据的量化分析，不构成投资建议。护城河评级可能随行业和竞争环境变化。
首版展示近期 SEC Forms 3、4、5 备案活动。尚未解析单笔买入/卖出交易。
资本结构
现金流
免责声明：本站内容不构成投资建议。数据来源于SEC EDGAR和Polygon.io。过往业绩不代表未来表现。投资决策前请自行研究。